Fragment-Based Discovery of KLK6 and KLK7 Inhibitors
Abstract
Human tissue kallikreins are serine proteases implicated in the pathogenesis of neurodegenerative diseases, skin disorders, and various cancers. Despite their therapeutic relevance, the development of selective small-molecule inhibitors for these enzymes has been limited compared to other serine proteases. To address this, we implemented a fragment-based virtual screening (FBVS) strategy to identify chemically tractable starting points for the inhibition of KLK6 and KLK7. The computational workflow, combining structure-based docking tailored to serine protease active sites, was experimentally validated using in vitro enzymatic assays. Notably, the approach yielded hit rates (IC50 ≤ 100 μM) ranging from 4% (KLK7) to 21.6% (KLK6), underscoring both the robustness of the screening cascade and the druggability of these targets. Preliminary structure–activity relationship analysis identified fragment 69 as a potent and ligand-efficient KLK6 inhibitor (IC50 = 2.1 μM, LE = 0.43). For KLK7, a distinct neutral 2-hydroxyquinoline fragment (38) was validated as a ligand-efficient hit (IC50 = 43.3 μM; LE = 0.46). Overall, this study demonstrates that kallikrein-related peptidases are amenable to fragment-based discovery and provides chemically simple, highly ligand-efficient fragments that serve as promising starting points for lead optimization targeting kallikrein-driven pathologies.
Related
- Fragment-based drug discovery strategy reveals an unprecedented allosteric binding site in Mycobacterium tuberculosis DNA gyrase
- ML-QSAR and Fragment Selectivity for the Identification of Fourth-Generation EGFRL858R/T790M/C797S Inhibitors
- Fragment‐Linked Purine Derivatives as Inhibitors of (p)ppGpp Synthetases: Design, Synthesis, and Structure‐Activity Relationships
- Discovery of natural flavanones as potential PRMT4 inhibitors with antiproliferative activity against colorectal cancer cells
- Prospective discovery of LasB inhibitors by integrating generative design, free energy ranking, and experimental validation
BibTeX
@article{freitas2026fragmentbased,
title = {{Fragment-Based Discovery of KLK6 and KLK7 Inhibitors}},
author = {Renato Ferreira de Freitas and Feryel Soualmia and Rilès Boumali and Yasmine Harrak and Chahrazade El Amri},
journal = {Journal of Chemical Information and Modeling},
year = {2026},
month = aug,
doi = {10.1021/acs.jcim.6c02059},
url = {https://hal.science/hal-05739951v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fragment-Based Discovery of KLK6 and KLK7 Inhibitors
AU - Renato Ferreira de Freitas
AU - Feryel Soualmia
AU - Rilès Boumali
AU - Yasmine Harrak
AU - Chahrazade El Amri
PY - 2026
DA - 2026/08/05
JO - Journal of Chemical Information and Modeling
DO - 10.1021/acs.jcim.6c02059
UR - https://hal.science/hal-05739951v1
AB - Human tissue kallikreins are serine proteases implicated in the pathogenesis of neurodegenerative diseases, skin disorders, and various cancers. Despite their therapeutic relevance, the development of selective small-molecule inhibitors for these enzymes has been limited compared to other serine proteases. To address this, we implemented a fragment-based virtual screening (FBVS) strategy to identify chemically tractable starting points for the inhibition of KLK6 and KLK7. The computational workflow, combining structure-based docking tailored to serine protease active sites, was experimentally validated using in vitro enzymatic assays. Notably, the approach yielded hit rates (IC50 ≤ 100 μM) ranging from 4% (KLK7) to 21.6% (KLK6), underscoring both the robustness of the screening cascade and the druggability of these targets. Preliminary structure–activity relationship analysis identified fragment 69 as a potent and ligand-efficient KLK6 inhibitor (IC50 = 2.1 μM, LE = 0.43). For KLK7, a distinct neutral 2-hydroxyquinoline fragment (38) was validated as a ligand-efficient hit (IC50 = 43.3 μM; LE = 0.46). Overall, this study demonstrates that kallikrein-related peptidases are amenable to fragment-based discovery and provides chemically simple, highly ligand-efficient fragments that serve as promising starting points for lead optimization targeting kallikrein-driven pathologies.
SN - 1549-9596
SN - 1549-960X
ER -